Request Pricing

Global Infectious Disease Situation Update

Reporting Period: April 1–7, 2026

The AeroClenz Chief Medical Officer periodically reviews publicly available infectious disease surveillance reports from organizations such as the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and European Centre for Disease Prevention and Control (ECDC).

These summaries are intended to provide general awareness of global infectious disease activity relevant to international travel, healthcare systems, and high-traffic indoor environments.

This information is provided for situational awareness only and does not constitute medical advice.

Key Takeaways

For the period of April 1–7, 2026, several notable global infectious disease trends were observed:

• Measles continues to present a significant disruption risk due to high transmissibility and ongoing global outbreaks
• Seasonal respiratory viruses are declining but remain present across multiple regions
• Cholera activity persists in multiple countries, particularly in infrastructure-limited settings
• Chikungunya remains a relevant travel-associated risk in the western Indian Ocean region
• High-consequence pathogens remain contained but continue to be monitored

Top 5 Signals

1) Measles remains the highest disruption risk per case

CDC’s most recent update reports 1,487 confirmed measles cases in the United States as of March 19, 2026, with approximately 94% associated with outbreaks.

Global surveillance continues to indicate measles activity across multiple regions, reinforcing its role as a highly transmissible disease with the potential for rapid spread through travel networks.

2) Respiratory virus season is declining, but not over

WHO reports that by week 12:

• Global influenza positivity has fallen below 10%
• SARS-CoV-2 activity remains low
• RSV activity remains stable at low levels

These trends indicate improving conditions, though respiratory viruses remain present.

3) Cholera remains a significant global concern

WHO continues to report multi-country cholera activity, with 18,715 cases and 269 deaths recorded in February 2026, representing an increase in mortality compared to January.

Cholera risk remains closely associated with water, sanitation, and healthcare infrastructure conditions.

4) Chikungunya remains a travel-associated risk

Chikungunya transmission in the Seychelles continues to be monitored by public-health agencies.

CDC maintains a Level 2 travel notice, and ECDC has previously documented increases in travel-associated cases linked to the region.

5) High-consequence zoonotic threats remain contained

WHO continues to assess recent Nipah virus events in India and Bangladesh as low risk at regional and global levels.

Ebola and Marburg outbreaks previously reported in the Democratic Republic of Congo and Ethiopia, respectively, remain in post-outbreak status.

Global Situation Overview

Respiratory Viruses

The global respiratory disease picture continues to improve.

WHO’s most recent update indicates:

• Declining influenza detections globally
• Influenza positivity below 10%
• Low SARS-CoV-2 activity
• Stable, low RSV activity

As the season progresses, influenza B is accounting for a larger share of detections.

Measles

Measles remains one of the most impactful infectious diseases in this update due to:

• High transmissibility
• Amplification through international travel
• Resource-intensive contact tracing

CDC data confirms continued outbreak activity in 2026, alongside ongoing global transmission.

Air Travel and Measles Exposure

Public-health guidance continues to emphasize that measles cases associated with air travel can result in extensive contact investigations.

Guidance also highlights the importance of recognizing potential symptoms during travel and ensuring timely communication with public-health authorities when cases are suspected.

Cholera

Cholera continues to be reported across multiple regions, particularly in areas where water and sanitation infrastructure is limited.

Recent updates indicate a notable increase in deaths relative to case counts, suggesting continued severity in affected areas.

Mpox

Mpox continues to be monitored globally, with ongoing reporting of clade Ib-associated activity and continued transmission in certain regions.

While not the dominant signal during this reporting period, it remains a relevant public-health consideration.

Arboviruses: Chikungunya and Dengue

Chikungunya activity in the Seychelles remains a relevant travel-associated signal.

Public-health agencies continue to emphasize mosquito precautions and awareness for travelers to affected regions.

Dengue remains a significant global burden, particularly in the Americas, though recent data suggests lower activity compared to the same period in 2025.

High-Consequence Pathogens

Nipah virus:
Recent events remain limited, with no evidence of sustained transmission.

Ebola and Marburg viruses:
No active outbreaks are currently reported. Previous outbreaks have been declared contained following appropriate monitoring periods.

These pathogens continue to be monitored due to their potential severity despite low current transmission risk.

Summary

The global infectious disease landscape for early April 2026 reflects improving respiratory virus trends alongside continued monitoring of high-impact and travel-associated risks.

Key themes include:

• Measles as the most significant disruption risk per individual case
• Declining but ongoing respiratory virus activity
• Persistent cholera transmission in infrastructure-limited settings
• Continued relevance of chikungunya as a travel-associated risk
• Contained but closely monitored high-consequence pathogens

Public-health surveillance agencies continue to monitor these developments and publish updates as new information becomes available.

Sources referenced in this summary include the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the European Centre for Disease Prevention and Control (ECDC), and peer-reviewed literature, including the Journal of Travel Medicine.

To learn more about AeroClenz, visit www.aeroclenz.com. Follow AeroClenz on social media for updates on research and technology developments.LinkedIn:https://www.linkedin.com/company/aeroclenz
Facebook:https://www.facebook.com/AeroClenz
Instagram:https://www.instagram.com/aeroclenz_

Get Updates Automatically
Translate »
Scroll to Top

Michael Stroup

Chief Operations Officer

Michael is a results-driven leader with 20 years of experience improving operations to achieve greater organizational effectiveness, productivity, and performance across multiple industries. Most recently Michael served as Integration Engineering Manager at CooperSurgical, a leading fertility medical device manufacturer. Prior to CSI, he has a proven track record of driving operational and engineering excellence within medical device, food, electronics and automotive industries by leading day to day operations and providing effective strategic leadership/execution.  His expertise includes, but is not limited to, global production set up, process improvements, machinery design and compliance. Michaels holds a Bachelor of Science in Mechanical Engineering Technology and Industrial Automotive Technology from Indiana State University and a Master of Science in Industrial Technology from Indiana State University.

Matt Saberton

CEO, Founder, Co-Inventor

Matt has been passionate about aviation from a young age, earning his private pilot’s license in high school. After obtaining a degree in Aviation and Aerospace Science, he began his career as a flight instructor and then became an air ambulance pilot, where he recognized the importance of cabin cleanliness.

Rising through the ranks at one of the largest worldwide charter airlines, Matt became Captain and later Chief Pilot, gaining deep insights into maintaining safe environments in aviation. This experience led him to found Aeroclenz, Inc., where he now serves as CEO.

Under his leadership, Aeroclenz has transitioned from an aerospace-focused company to a leader in UV disinfection solutions, offering custom products for both aerospace and terrestrial indoor applications. While the company’s roots are in aviation, its technologies now ensure high standards of cleanliness across various industries.

Jameson Trettenero

Director of Marketing

Jameson is a seasoned marketing expert with experience driving strategic marketing initiatives across a diverse array of industries. In his role, Jameson leads the marketing efforts with a focus on innovative growth strategies, brand elevation, and data-driven decision-making that align with the company’s overarching business goals.

Before joining Aeroclenz, Jameson held key leadership positions at top-tier digital agencies. In his agency experience, he spearheaded multi-divisional teams across disciplines including SEO, Paid Media, Analytics, and Creative. His strategic oversight and client-centric approach significantly enhanced client retention and business growth, particularly across enterprise-level accounts.

Jameson’s expertise extends to managing complex client relationships, advising C-level executives, and navigating the intricacies of the marketing landscape. His ability to harmonize creativity with analytics has consistently driven measurable success for clients, from Fortune 500 companies to emerging brands.